• 1
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Treatment of early breast cancer. Vol. 1. Worldwide evidence, 1985–1990. Oxford: Oxford University Press, 1990.
  • 2
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992; 339: 115.
  • 3
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998; 351: 14511467.
  • 4
    Sacco M, Valentini M, Belfiglio M, et al. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01. J Clin Oncol. 2003; 21: 22762281.
  • 5
    Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst. 1996; 88: 18341839.
  • 6
    Delozier T, Spielmann M, Mace-Lesec'h J, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. J Clin Oncol. 2000; 18: 35073512.
  • 7
    Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996; 88: 15431549.
  • 8
    International Union Against Cancer. TNM. Classification of malignant tumours. Berlin: Springer, 1987.
  • 9
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 10
    Cox DR. Regression models and life tables. J R Stat Soc (B). 1972; 34: 187220.
  • 11
    Nicolucci A, Belfiglio M, Pellegrini F, et al. In replay. J Clin Oncol. 2004; 22: 1165.
  • 12
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 13
    Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 6062.
  • 14
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687717.